ID   PTPRE_HUMAN             Reviewed;         700 AA.
AC   P23469; Q13345; Q5VWH3; Q5VWH4; Q96KQ6;
DT   01-NOV-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1991, sequence version 1.
DT   10-MAY-2017, entry version 169.
DE   RecName: Full=Receptor-type tyrosine-protein phosphatase epsilon;
DE            Short=Protein-tyrosine phosphatase epsilon;
DE            Short=R-PTP-epsilon;
DE            EC=3.1.3.48;
DE   Flags: Precursor;
GN   Name=PTPRE;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2170109;
RA   Krueger N.X., Streuli M., Saito H.;
RT   "Structural diversity and evolution of human receptor-like protein
RT   tyrosine phosphatases.";
RL   EMBO J. 9:3241-3252(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=12121439; DOI=10.1046/j.1365-3083.2002.01126.x;
RA   Wabakken T.K., Hauge H., Finne E.F., Wiedlocha A., Aasheim H.-C.;
RT   "Expression of human protein tyrosine phosphatase epsilon in
RT   leucocytes: a potential ERK pathway-regulating phosphatase.";
RL   Scand. J. Immunol. 56:195-203(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-98 (ISOFORM 2), SUBCELLULAR LOCATION,
RP   AND INDUCTION.
RX   PubMed=8618876; DOI=10.1073/pnas.92.26.12235;
RA   Elson A., Leder P.;
RT   "Identification of a cytoplasmic, phorbol ester-inducible isoform of
RT   protein tyrosine phosphatase epsilon.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:12235-12239(1995).
RN   [8]
RP   TISSUE SPECIFICITY.
RX   PubMed=8610169; DOI=10.1073/pnas.93.7.3068;
RA   Schmidt A., Rutledge S.J., Endo N., Opas E., Tanaka H., Wesolowski G.,
RA   Leu C.T., Huang Z., Ramachandaran C., Rodan S.B., Rodan G.A.;
RT   "Protein-tyrosine phosphatase activity regulates osteoclast formation
RT   and function: inhibition by alendronate.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:3068-3073(1996).
RN   [9]
RP   ALTERNATIVE PROMOTER USAGE.
RX   PubMed=9914474; DOI=10.1046/j.1432-1327.1999.00004.x;
RA   Tanuma N., Nakamura K., Kikuchi K.;
RT   "Distinct promoters control transmembrane and cytosolic protein
RT   tyrosine phosphatase epsilon expression during macrophage
RT   differentiation.";
RL   Eur. J. Biochem. 259:46-54(1999).
RN   [10]
RP   IDENTIFICATION (ISOFORM 3), ALTERNATIVE INITIATION, SUBCELLULAR
RP   LOCATION, PROTEOLYTIC PROCESSING, PHOSPHORYLATION, GLYCOSYLATION, AND
RP   INTERACTION WITH GRB2.
RX   PubMed=10980613; DOI=10.1038/sj.onc.1203790;
RA   Gil-Henn H., Volohonsky G., Toledano-Katchalski H., Gandre S.,
RA   Elson A.;
RT   "Generation of novel cytoplasmic forms of protein tyrosine phosphatase
RT   epsilon by proteolytic processing and translational control.";
RL   Oncogene 19:4375-4384(2000).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-696, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 107-697, AND SUBUNIT.
RX   PubMed=19167335; DOI=10.1016/j.cell.2008.11.038;
RA   Barr A.J., Ugochukwu E., Lee W.H., King O.N.F., Filippakopoulos P.,
RA   Alfano I., Savitsky P., Burgess-Brown N.A., Mueller S., Knapp S.;
RT   "Large-scale structural analysis of the classical human protein
RT   tyrosine phosphatome.";
RL   Cell 136:352-363(2009).
CC   -!- FUNCTION: Isoform 1 plays a critical role in signaling
CC       transduction pathways and phosphoprotein network topology in red
CC       blood cells. May play a role in osteoclast formation and function
CC       (By similarity). {ECO:0000250}.
CC   -!- FUNCTION: Isoform 2 acts as a negative regulator of insulin
CC       receptor (IR) signaling in skeletal muscle. Regulates insulin-
CC       induced tyrosine phosphorylation of insulin receptor (IR) and
CC       insulin receptor substrate 1 (IRS-1), phosphorylation of protein
CC       kinase B and glycogen synthase kinase-3 and insulin induced
CC       stimulation of glucose uptake (By similarity). {ECO:0000250}.
CC   -!- FUNCTION: Isoform 1 and isoform 2 act as a negative regulator of
CC       FceRI-mediated signal transduction leading to cytokine production
CC       and degranulation, most likely by acting at the level of SYK to
CC       affect downstream events such as phosphorylation of SLP76 and LAT
CC       and mobilization of Ca(2+). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: Protein tyrosine phosphate + H(2)O = protein
CC       tyrosine + phosphate. {ECO:0000255|PROSITE-ProRule:PRU10044}.
CC   -!- SUBUNIT: Monomer. Isoform 2: Homodimer. Can form oligomers.
CC       Dimerization is increased by oxidative stress and decreased by
CC       EGFR. Isoform 2 interacts with GRB2 (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm. Note=Predominantly
CC       cytoplasmic. A small fraction is also associated with nucleus and
CC       membrane. Insulin induces translocation to the membrane (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative initiation; Named isoforms=3;
CC       Name=1; Synonyms=PTPeM, RPTPe, tm-PTPe;
CC         IsoId=P23469-1; Sequence=Displayed;
CC         Note=Produced by alternative promoter usage.;
CC       Name=2; Synonyms=PTPeC, cyt-PTPe;
CC         IsoId=P23469-2; Sequence=VSP_007778;
CC         Note=Produced by alternative promoter usage.;
CC       Name=3; Synonyms=p67;
CC         IsoId=P23469-3; Sequence=VSP_038490;
CC         Note=Produced by alternative initiation at Met-86 of isoform 1.;
CC   -!- TISSUE SPECIFICITY: Expressed in giant cell tumor (osteoclastoma
CC       rich in multinucleated osteoclastic cells).
CC       {ECO:0000269|PubMed:8610169}.
CC   -!- INDUCTION: Up-regulated by 12-O-tetradecanoylphorbol-13-acetate
CC       (TPA) in HL-60 cells. {ECO:0000269|PubMed:8618876}.
CC   -!- DOMAIN: The tyrosine-protein phosphatase 2 domain (D2) mediates
CC       dimerization. The extreme N- and C- termini of the D2 domain act
CC       to inhibit dimerization and removal of these sequences increases
CC       dimerization and inhibits enzyme activity (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: A catalytically active cytoplasmic form (p65) is produced by
CC       proteolytic cleavage of either isoform 1, isoform 2 or isoform 3.
CC       {ECO:0000269|PubMed:10980613}.
CC   -!- PTM: Isoform 1 and isoform 2 are phosphorylated on tyrosine
CC       residues by tyrosine kinase Neu. {ECO:0000269|PubMed:10980613}.
CC   -!- PTM: Isoform 1 is glycosylated. {ECO:0000269|PubMed:10980613}.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family.
CC       Receptor class 4 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC50324.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the C-terminal part.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X54134; CAA38069.1; -; mRNA.
DR   EMBL; AJ315969; CAC86583.1; -; mRNA.
DR   EMBL; AK291828; BAF84517.1; -; mRNA.
DR   EMBL; AL390236; CAH73173.1; -; Genomic_DNA.
DR   EMBL; AL390236; CAH73174.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49180.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49181.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49182.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49184.1; -; Genomic_DNA.
DR   EMBL; BC050062; AAH50062.1; -; mRNA.
DR   EMBL; U36623; AAC50324.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS7657.1; -. [P23469-1]
DR   CCDS; CCDS7658.1; -. [P23469-2]
DR   PIR; S12053; S12053.
DR   RefSeq; NP_001303605.1; NM_001316676.1.
DR   RefSeq; NP_001303606.1; NM_001316677.1. [P23469-1]
DR   RefSeq; NP_001310283.1; NM_001323354.1. [P23469-1]
DR   RefSeq; NP_006495.1; NM_006504.5. [P23469-1]
DR   RefSeq; NP_569119.1; NM_130435.4. [P23469-2]
DR   RefSeq; XP_005252748.1; XM_005252691.2. [P23469-1]
DR   RefSeq; XP_016871957.1; XM_017016468.1. [P23469-1]
DR   UniGene; Hs.127022; -.
DR   PDB; 2JJD; X-ray; 3.20 A; A/B/C/D/E/F=107-697.
DR   PDBsum; 2JJD; -.
DR   ProteinModelPortal; P23469; -.
DR   SMR; P23469; -.
DR   BioGrid; 111755; 6.
DR   IntAct; P23469; 3.
DR   MINT; MINT-1349810; -.
DR   STRING; 9606.ENSP00000254667; -.
DR   BindingDB; P23469; -.
DR   ChEMBL; CHEMBL4850; -.
DR   DrugBank; DB00630; Alendronic acid.
DR   DEPOD; P23469; -.
DR   iPTMnet; P23469; -.
DR   PhosphoSitePlus; P23469; -.
DR   BioMuta; PTPRE; -.
DR   DMDM; 126471; -.
DR   EPD; P23469; -.
DR   PaxDb; P23469; -.
DR   PeptideAtlas; P23469; -.
DR   PRIDE; P23469; -.
DR   Ensembl; ENST00000254667; ENSP00000254667; ENSG00000132334. [P23469-1]
DR   Ensembl; ENST00000306042; ENSP00000303350; ENSG00000132334. [P23469-2]
DR   GeneID; 5791; -.
DR   KEGG; hsa:5791; -.
DR   UCSC; uc001lkb.4; human. [P23469-1]
DR   CTD; 5791; -.
DR   DisGeNET; 5791; -.
DR   GeneCards; PTPRE; -.
DR   HGNC; HGNC:9669; PTPRE.
DR   HPA; HPA015870; -.
DR   HPA; HPA021872; -.
DR   MIM; 600926; gene.
DR   neXtProt; NX_P23469; -.
DR   OpenTargets; ENSG00000132334; -.
DR   PharmGKB; PA34014; -.
DR   eggNOG; KOG4228; Eukaryota.
DR   eggNOG; COG5599; LUCA.
DR   GeneTree; ENSGT00760000118900; -.
DR   HOGENOM; HOG000231465; -.
DR   HOVERGEN; HBG053758; -.
DR   InParanoid; P23469; -.
DR   KO; K18033; -.
DR   OMA; ANDKKMP; -.
DR   OrthoDB; EOG091G02ID; -.
DR   PhylomeDB; P23469; -.
DR   TreeFam; TF351829; -.
DR   BRENDA; 3.1.3.48; 2681.
DR   SignaLink; P23469; -.
DR   SIGNOR; P23469; -.
DR   ChiTaRS; PTPRE; human.
DR   EvolutionaryTrace; P23469; -.
DR   GeneWiki; PTPRE; -.
DR   GenomeRNAi; 5791; -.
DR   PRO; PR:P23469; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000132334; -.
DR   CleanEx; HS_PTPRE; -.
DR   ExpressionAtlas; P23469; baseline and differential.
DR   Genevisible; P23469; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IEA:Ensembl.
DR   GO; GO:0005001; F:transmembrane receptor protein tyrosine phosphatase activity; TAS:ProtInc.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0006470; P:protein dephosphorylation; TAS:ProtInc.
DR   GO; GO:0033003; P:regulation of mast cell activation; IEA:Ensembl.
DR   GO; GO:0007185; P:transmembrane receptor protein tyrosine phosphatase signaling pathway; IEA:Ensembl.
DR   Gene3D; 3.90.190.10; -; 2.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR000242; PTPase_domain.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR003595; Tyr_Pase_cat.
DR   InterPro; IPR016336; Tyr_Pase_rcpt_a/e-type.
DR   InterPro; IPR000387; TYR_PHOSPHATASE_dom.
DR   Pfam; PF00102; Y_phosphatase; 2.
DR   PIRSF; PIRSF002006; PTPR_alpha_epsilon; 1.
DR   PRINTS; PR00700; PRTYPHPHTASE.
DR   SMART; SM00194; PTPc; 2.
DR   SMART; SM00404; PTPc_motif; 2.
DR   SUPFAM; SSF52799; SSF52799; 2.
DR   PROSITE; PS00383; TYR_PHOSPHATASE_1; 2.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 2.
DR   PROSITE; PS50055; TYR_PHOSPHATASE_PTP; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Alternative promoter usage;
KW   Cell membrane; Complete proteome; Cytoplasm; Glycoprotein; Hydrolase;
KW   Membrane; Phosphoprotein; Protein phosphatase; Reference proteome;
KW   Repeat; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   CHAIN        20    700       Receptor-type tyrosine-protein
FT                                phosphatase epsilon.
FT                                /FTId=PRO_0000025439.
FT   TOPO_DOM     20     46       Extracellular. {ECO:0000255}.
FT   TRANSMEM     47     69       Helical. {ECO:0000255}.
FT   TOPO_DOM     70    700       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      135    394       Tyrosine-protein phosphatase 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00160}.
FT   DOMAIN      426    689       Tyrosine-protein phosphatase 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00160}.
FT   REGION      335    341       Substrate binding. {ECO:0000250}.
FT   ACT_SITE    335    335       Phosphocysteine intermediate.
FT                                {ECO:0000250}.
FT   ACT_SITE    630    630       Phosphocysteine intermediate.
FT                                {ECO:0000250}.
FT   BINDING     303    303       Substrate. {ECO:0000250}.
FT   BINDING     379    379       Substrate. {ECO:0000250}.
FT   MOD_RES     696    696       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   CARBOHYD     23     23       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     30     30       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ       1     85       Missing (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_038490.
FT   VAR_SEQ       1     70       MEPLCPLLLVGFSLPLARALRGNETTADSNETTTTSGPPDP
FT                                GASQPLLAWLLLPLLLLLLVLLLAAYFFR -> MSNRSSFS
FT                                RLTW (in isoform 2).
FT                                {ECO:0000303|PubMed:12121439,
FT                                ECO:0000303|PubMed:8618876}.
FT                                /FTId=VSP_007778.
FT   CONFLICT    516    516       E -> D (in Ref. 2; CAC86583).
FT                                {ECO:0000305}.
FT   HELIX       117    119       {ECO:0000244|PDB:2JJD}.
FT   HELIX       120    126       {ECO:0000244|PDB:2JJD}.
FT   HELIX       139    141       {ECO:0000244|PDB:2JJD}.
FT   TURN        152    155       {ECO:0000244|PDB:2JJD}.
FT   HELIX       157    162       {ECO:0000244|PDB:2JJD}.
FT   STRAND      172    177       {ECO:0000244|PDB:2JJD}.
FT   TURN        185    188       {ECO:0000244|PDB:2JJD}.
FT   STRAND      189    197       {ECO:0000244|PDB:2JJD}.
FT   STRAND      200    207       {ECO:0000244|PDB:2JJD}.
FT   HELIX       212    214       {ECO:0000244|PDB:2JJD}.
FT   HELIX       215    224       {ECO:0000244|PDB:2JJD}.
FT   STRAND      229    232       {ECO:0000244|PDB:2JJD}.
FT   STRAND      236    238       {ECO:0000244|PDB:2JJD}.
FT   STRAND      250    256       {ECO:0000244|PDB:2JJD}.
FT   STRAND      259    268       {ECO:0000244|PDB:2JJD}.
FT   STRAND      270    280       {ECO:0000244|PDB:2JJD}.
FT   STRAND      291    298       {ECO:0000244|PDB:2JJD}.
FT   STRAND      303    305       {ECO:0000244|PDB:2JJD}.
FT   HELIX       311    323       {ECO:0000244|PDB:2JJD}.
FT   STRAND      331    334       {ECO:0000244|PDB:2JJD}.
FT   STRAND      336    340       {ECO:0000244|PDB:2JJD}.
FT   HELIX       341    358       {ECO:0000244|PDB:2JJD}.
FT   STRAND      359    361       {ECO:0000244|PDB:2JJD}.
FT   HELIX       363    371       {ECO:0000244|PDB:2JJD}.
FT   HELIX       381    396       {ECO:0000244|PDB:2JJD}.
FT   HELIX       426    434       {ECO:0000244|PDB:2JJD}.
FT   HELIX       444    447       {ECO:0000244|PDB:2JJD}.
FT   HELIX       449    452       {ECO:0000244|PDB:2JJD}.
FT   STRAND      464    469       {ECO:0000244|PDB:2JJD}.
FT   STRAND      481    487       {ECO:0000244|PDB:2JJD}.
FT   STRAND      490    492       {ECO:0000244|PDB:2JJD}.
FT   STRAND      496    499       {ECO:0000244|PDB:2JJD}.
FT   TURN        504    506       {ECO:0000244|PDB:2JJD}.
FT   HELIX       507    516       {ECO:0000244|PDB:2JJD}.
FT   STRAND      521    524       {ECO:0000244|PDB:2JJD}.
FT   STRAND      528    530       {ECO:0000244|PDB:2JJD}.
FT   STRAND      542    548       {ECO:0000244|PDB:2JJD}.
FT   STRAND      551    560       {ECO:0000244|PDB:2JJD}.
FT   STRAND      562    573       {ECO:0000244|PDB:2JJD}.
FT   STRAND      584    592       {ECO:0000244|PDB:2JJD}.
FT   STRAND      597    599       {ECO:0000244|PDB:2JJD}.
FT   HELIX       605    620       {ECO:0000244|PDB:2JJD}.
FT   STRAND      626    629       {ECO:0000244|PDB:2JJD}.
FT   STRAND      631    635       {ECO:0000244|PDB:2JJD}.
FT   HELIX       636    653       {ECO:0000244|PDB:2JJD}.
FT   STRAND      654    656       {ECO:0000244|PDB:2JJD}.
FT   HELIX       658    666       {ECO:0000244|PDB:2JJD}.
FT   HELIX       676    690       {ECO:0000244|PDB:2JJD}.
SQ   SEQUENCE   700 AA;  80642 MW;  D096BCADCEA65708 CRC64;
     MEPLCPLLLV GFSLPLARAL RGNETTADSN ETTTTSGPPD PGASQPLLAW LLLPLLLLLL
     VLLLAAYFFR FRKQRKAVVS TSDKKMPNGI LEEQEQQRVM LLSRSPSGPK KYFPIPVEHL
     EEEIRIRSAD DCKQFREEFN SLPSGHIQGT FELANKEENR EKNRYPNILP NDHSRVILSQ
     LDGIPCSDYI NASYIDGYKE KNKFIAAQGP KQETVNDFWR MVWEQKSATI VMLTNLKERK
     EEKCHQYWPD QGCWTYGNIR VCVEDCVVLV DYTIRKFCIQ PQLPDGCKAP RLVSQLHFTS
     WPDFGVPFTP IGMLKFLKKV KTLNPVHAGP IVVHCSAGVG RTGTFIVIDA MMAMMHAEQK
     VDVFEFVSRI RNQRPQMVQT DMQYTFIYQA LLEYYLYGDT ELDVSSLEKH LQTMHGTTTH
     FDKIGLEEEF RKLTNVRIMK ENMRTGNLPA NMKKARVIQI IPYDFNRVIL SMKRGQEYTD
     YINASFIDGY RQKDYFIATQ GPLAHTVEDF WRMIWEWKSH TIVMLTEVQE REQDKCYQYW
     PTEGSVTHGE ITIEIKNDTL SEAISIRDFL VTLNQPQARQ EEQVRVVRQF HFHGWPEIGI
     PAEGKGMIDL IAAVQKQQQQ TGNHPITVHC SAGAGRTGTF IALSNILERV KAEGLLDVFQ
     AVKSLRLQRP HMVQTLEQYE FCYKVVQDFI DIFSDYANFK
//
